Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma
Michele Dal Bo, Elena De Mattia, Lorena Baboçi, et al.
Drug Resistance Updates (2020) Vol. 51, pp. 100702-100702
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
Tianyu Tang, Xing Huang, Gang Zhang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 355
Hypoxia as a driver of resistance to immunotherapy
Joanna Kopecka, Iris C. Salaroglio, Elisabeth Pérez-Ruíz, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100787-100787
Open Access | Times Cited: 174
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
Elisabeth Pérez-Ruíz, Ignacio Melero, Joanna Kopecka, et al.
Drug Resistance Updates (2020) Vol. 53, pp. 100718-100718
Open Access | Times Cited: 164
Recent advances in systemic therapy for hepatocellular carcinoma
Huajun Zhang, Wuyang Zhang, Longying Jiang, et al.
Biomarker Research (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 162
Novel nanomedicines to overcome cancer multidrug resistance
Zhenwei Su, Shaowei Dong, Shan‐Chao Zhao, et al.
Drug Resistance Updates (2021) Vol. 58, pp. 100777-100777
Closed Access | Times Cited: 137
Biological impact and therapeutic perspective of targeting PI3K/Akt signaling in hepatocellular carcinoma: Promises and Challenges
Mahshid Deldar Abad Paskeh, Fatemeh Ghadyani, Mehrdad Hashemi, et al.
Pharmacological Research (2022) Vol. 187, pp. 106553-106553
Open Access | Times Cited: 85
Selenium Nanoparticles Enhance NK Cell‐Mediated Tumoricidal Activity in Malignant Pleural Effusion via the TrxR1‐IL‐18RAP‐pSTAT3 Pathway
Shaowei Liu, Naijian Li, Haoqiang Lai, et al.
Advanced Functional Materials (2024) Vol. 34, Iss. 30
Closed Access | Times Cited: 17
Impact of cancer metabolism on therapy resistance – Clinical implications
Ana Cristina Gonçalves, Elena Richiardone, Joana Jorge, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100797-100797
Open Access | Times Cited: 89
Repurposing old drugs to fight multidrug resistant cancers
Jelena Dinić, Thomas Efferth, Alfonso T. García‐Sosa, et al.
Drug Resistance Updates (2020) Vol. 52, pp. 100713-100713
Open Access | Times Cited: 80
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
Michela Chiappa, Federica Guffanti, Francesco Bertoni, et al.
Drug Resistance Updates (2021) Vol. 55, pp. 100744-100744
Closed Access | Times Cited: 79
Liver Inflammation and Hepatobiliary Cancers
Valentina Leone, Adnan Ali, Achim Weber, et al.
Trends in cancer (2021) Vol. 7, Iss. 7, pp. 606-623
Closed Access | Times Cited: 61
Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma
Xiaomeng Dai, Yixuan Guo, Yan Hu, et al.
Theranostics (2021) Vol. 11, Iss. 7, pp. 3489-3501
Open Access | Times Cited: 57
The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications
Philippe Icard, Luca Simula, Ludovic Fournel, et al.
Drug Resistance Updates (2022) Vol. 63, pp. 100852-100852
Open Access | Times Cited: 40
EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies
Bohan Wang, Yachong Liu, Zhibin Liao, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 27
Bright future or blind alley? CAR-T cell therapy for solid tumors
Kai Zhang, Hong Chen, Fuqiang Li, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 26
Sodium citrate targeting Ca2+/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer
Yulun Wu, Chaoran Jia, Wei Liu, et al.
Journal of Advanced Research (2024) Vol. 65, pp. 89-104
Open Access | Times Cited: 11
New Opportunities in the Systemic Treatment of Hepatocellular Carcinoma—Today and Tomorrow
Rafał Becht, Kajetan Kiełbowski, Michał Wasilewicz
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1456-1456
Open Access | Times Cited: 10
Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance
Ting Jiang, Xisha Chen, Xingcong Ren, et al.
Drug Resistance Updates (2021) Vol. 56, pp. 100752-100752
Closed Access | Times Cited: 47
Upregulation of Superenhancer‐Driven LncRNA FASRL by USF1 Promotes De Novo Fatty Acid Biosynthesis to Exacerbate Hepatocellular Carcinoma
Jiangyun Peng, Dian‐Kui Cai, Ren‐Li Zeng, et al.
Advanced Science (2022) Vol. 10, Iss. 1
Open Access | Times Cited: 32
Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma
Linfu Zhou, Yao Li, Di‐Wei Zheng, et al.
Deleted Journal (2024) Vol. 32, Iss. 2, pp. 200817-200817
Open Access | Times Cited: 8
Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances
Tingrui Zhang, Zongguang Tai, Fengze Miao, et al.
Journal of Controlled Release (2024) Vol. 368, pp. 372-396
Closed Access | Times Cited: 7
Yes-associated protein and transcriptional coactivator with PDZ-binding motif as new targets in cardiovascular diseases
Yue Yu, Xingli Su, Qiaohong Qin, et al.
Pharmacological Research (2020) Vol. 159, pp. 105009-105009
Closed Access | Times Cited: 41
Advances of Targeted Therapy for Hepatocellular Carcinoma
Mengke Niu, Ming Yi, Ning Li, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 36
Why may citrate sodium significantly increase the effectiveness of transarterial chemoembolization in hepatocellular carcinoma?
Philippe Icard, Luca Simula, Zherui Wu, et al.
Drug Resistance Updates (2021) Vol. 59, pp. 100790-100790
Open Access | Times Cited: 35
Nanomedicines for Overcoming Cancer Drug Resistance
Tingting Hu, Hanlin Gong, Jiayue Xu, et al.
Pharmaceutics (2022) Vol. 14, Iss. 8, pp. 1606-1606
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top